Product Description
Toray Industries was developing trk-170, an oral ITGA4-B7 Antagonist for treatment of CD.
Mechanisms of Action: a4b7 Inhibitor
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Toray Industries
Company Location:
Company Founding Year: 1926
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 2: Crohn Disease
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
2011-000854-44 |
2011-000854-44 | P2 |
Completed |
Crohn Disease |
2014-04-16 |
2022-03-13 |
Treatments |
|
NCT01345799 |
170CDT01 | P2 |
Completed |
Crohn Disease |
None |
2019-03-19 |
Treatments |
Recent News Events
Date |
Type |
Title |
|---|